Prof. Dr. Milen MinkovPediatrics, hematology and oncology

Prof. Milen Minkov, MD, PhD

Specialist in pediatrics and adolescent medicine with specialization in pediatric hematology and oncology. Head of the Research Center for Child Health, Growth and Development at Sigmund Freud University Vienna and of the International LCH Study Reference Center at St. Anna Children’s Cancer Research Institute (CCRI).

Languages: English, German, Bulgarian, Russian

Portrait of Prof. Milen Minkov
Peer-reviewed articles
146
Book chapters and consensus papers
20
Scientific presentations
98
Scientific awards
6

Career

Medical studies in Moscow, specialist training in Moscow and Vienna, then at St. Anna Children’s Hospital in Vienna until 2012. Since 2003, Prof. Minkov has cared for families at his private practice in Strasshof, northeast of Vienna.

Research interests

  • Langerhans cell histiocytosis and other histiocytic disorders
  • Pediatric hematology and oncology
  • Immune and inflammatory syndromes (HLH)
  • Health care structures and clinical guidelines

Research profiles

  1. 1991Graduated in medicine in Moscow
  2. 1991–1993Postdoctoral training at the Research Institute for Pediatric Hematology, Moscow (scholarship)
  3. 1996–2012St. Anna Children's Hospital, Vienna; from 2002 attending physician of the outpatient department for hematology, oncology and immunology
  4. since 2003Private pediatric practice (Wahlarzt) in Strasshof, near Vienna
  5. since 2012Principal investigator of the international LCH-IV study, with centers in 24 countries
  6. 2016–2019President of the Histiocyte Society
  7. since 2017Professor of Specialized Pediatrics, Sigmund Freud University Vienna
  8. since 2019President of the European Consortium for Histiocytosis (ECHO)
  9. since 2023Head of the Research Center for Child Health, Growth and Development, Sigmund Freud University Vienna

Awards and scholarships

  1. 2024Golden Pin Award of the Histiocyte Society, together with the Histiocytosis Association, for contributions to research on histiocytic disorders
  2. 2016“Honored Professor” of the Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow
  3. 2011Mark Nesbit Award in Clinical Science (as senior author; previously in 1997 as first author and in 2003 as co-author)
  4. 2003First poster prize, 41st annual meeting of the Austrian Society of Pediatrics and Adolescent Medicine, Salzburg
  5. 1991–1993Scholarship of the St. Cyril and St. Methodius International Foundation for postdoctoral training in Moscow
  6. 1986Scholarship of the Bulgarian government for medical studies in Moscow

Selected publications

A selection of work on Langerhans cell histiocytosis, including guidelines and results of international studies. The complete list is available in the Sigmund Freud University research profile.

  1. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years

    Haupt R, Minkov M, Astigarraga I, et al. Pediatric Blood & Cancer 2013;60(2):175–184 · Guideline of the Euro Histio Network

  2. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

    Gadner H, Minkov M, Grois N, et al. Blood 2013;121(25):5006–5014 · Results of the international LCH-III study

  3. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification

    Gadner H, Grois N, Pötschger U, Minkov M, et al. Blood 2008;111(5):2556–2562

  4. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry

    Minkov M, Steiner M, Pötschger U, et al. The Journal of Pediatrics 2008;153(5):700–705

  5. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator

    Minkov M, Grois N, Heitger A, et al. Medical and Pediatric Oncology 2002;39(6):581–585

  6. Disease response criteria in Langerhans cell histiocytosis: a global view

    Buhtoiarov IN, Minkov M, Vali R, Abla O. International Journal of Hematology 2025;121(6):756–766

  7. Long-term MAPK inhibition of childhood refractory Langerhans cell histiocytosis: an observational study of 288 patients

    Donadieu J, Evseev D, Pegoraro F, …, Minkov M. Blood Advances 2026;10(10):3733–3743

  8. Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: results from the European Consortium for Histiocytosis

    Pegoraro F, Chalard F, Evseev D, …, Minkov M, Henter JI, Sieni E, Donadieu J. HemaSphere 2026;10(6):e70392

  9. Standard Clinical Practice Recommendations for Pediatric-Onset Langerhans Cell Histiocytosis

    Donadieu J, Henter JI, Lehrnbecher T, Minkov M, et al. (ECHO). SIOPE / ERN PaedCan, 2020, Version 1.2 · Guideline of the European Consortium for Histiocytosis

Consultations

Prof. Minkov offers second opinions for children with blood disorders and cancer, including Langerhans cell histiocytosis, at his practice near Vienna. Consultations are available in English, German, Bulgarian and Russian.

Profil auf Deutsch

Request a consultation

Call us or send a short written request. We will tell you which records we need.

Phone

+43 2287 40909

Appointments only

Send a written request

CallDirections